What does GUCA stand for?

GPC Biotech AG (Frankfurt Stock Exchange: GPC, NASDAQ: GPCB) has announced that data from the double-blind, randomized satraplatin Phase 3 trial, the SPARC trial (Satraplatin and Prednisone Against Refractory Cancer) was presented at the 2009 American Society for Clinical Oncology (ASCO) Genitourinary Cancers Symposium in Orlando, Florida.

This review provides a brief overview of the presently accepted methods for noninvasive lymph node staging and thoroughly discusses lymphotrophic nanoparticle enhanced MR imaging: a technique that can be used for accurate detection of lymph node metastases and will likely play a major role in noninvasive lymph node staging in genitourinary cancer in the near future.

Contributors address the specifics of lymphomas, leukemias, breast cancer in females, lung cancer, cancers of the head and neck, gastrointestinal cancers, genitourinary cancer, gynecologic cancers, skin cancers and pediatric answers.

In addition, we continued to report positive data from the ongoing CB7630 Phase II clinical trials at the 2009 ASCO Genitourinary Cancers Symposium during the quarter.

Medical Center, and Fox Chase Cancer Center) have organized the 72 chapters into sections covering genitourinary cancer, head and neck cancer, endocrine tumors, breast cancer, thoracic tumors, gastrointestinal tumors, gynecological tumors, hematological malignancies, cutaneous malignancies, neurological malignancies, and pediatric malignancies.

for manufacture of 1,000 doses of CG201 vaccine for use in planned phase 1 and 2 clinical studies in bladder, ovarian and other genitourinary cancers to commence by year end.

These results were presented at the American Society of Clinical Oncology's Genitourinary Cancer Symposium on February 27, 2009.

GPC Biotech AG (Frankfurt Stock Exchange: GPC, NASDAQ: GPCB) today announced that data from the double-blind, randomized satraplatin Phase 3 trial, the SPARC trial (Satraplatin and Prednisone Against Refractory Cancer) are being presented at the 2009 American Society for Clinical Oncology (ASCO) Genitourinary Cancers Symposium in Orlando, Florida.